Cogent Biosciences, Inc.
COGT
$34.09
-$0.29-0.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 46.91% | 24.91% | 25.85% | 23.35% | 25.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.81% | 18.11% | 22.51% | 26.91% | 32.58% |
| Operating Income | -20.81% | -18.11% | -22.51% | -26.91% | -32.58% |
| Income Before Tax | -28.56% | -21.49% | -25.12% | -27.02% | -32.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.56% | -21.49% | -25.12% | -27.02% | -32.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.56% | -21.49% | -25.12% | -27.02% | -32.98% |
| EBIT | -20.81% | -18.11% | -22.51% | -26.91% | -32.58% |
| EBITDA | -20.96% | -18.23% | -22.67% | -27.13% | -32.85% |
| EPS Basic | 99.65% | 99.66% | 99.65% | 99.66% | -29,898.64% |
| Normalized Basic EPS | 99.65% | 99.66% | 99.66% | 99.66% | -30,022.54% |
| EPS Diluted | 99.65% | 99.66% | 99.65% | 99.66% | -29,898.64% |
| Normalized Diluted EPS | 99.65% | 99.66% | 99.66% | 99.66% | -30,022.54% |
| Average Basic Shares Outstanding | 60.75% | 60.90% | 65.08% | 75.22% | 0.75% |
| Average Diluted Shares Outstanding | 60.75% | 60.90% | 65.08% | 75.22% | 0.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |